Upgrade to SI Premium - Free Trial

Karyopharm Therapeutics (KPTI) Reports Positive Phase 1/2 Eltanexor Data

December 11, 2017 6:00 AM
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) today announced the presentation of Phase 1/2 clinical data for its novel, second-generation oral SINE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles